Friday, December 20, 2019 11:44:16 AM
My understanding is that there is a new process in Australia that can accelerate the approval of promising drugs after a successful Phase 2 study whereby you can begin selling the drug and continue collecting data into a phase 4 to achieve final approval.
Since DMAC increased the stroke study to 100 patients which is supposed to report topline phase 2 results data in 1Q/20, I'm wondering if they are applying for this "provisional approval?"
Any information or thoughts about this possibility would be appreciated.
Recent DMAC News
- DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024 • Business Wire • 05/02/2024 12:55:00 PM
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke • Business Wire • 04/17/2024 08:08:00 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results • Business Wire • 03/19/2024 08:15:00 PM
- DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference • Business Wire • 01/29/2024 09:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:23:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:12:31 PM
- DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer • Business Wire • 01/22/2024 01:23:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:47:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:39:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:30:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 09:37:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:52:34 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results • Business Wire • 11/13/2023 09:28:00 PM
- DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 • Business Wire • 11/09/2023 01:25:00 PM
- DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 • Business Wire • 11/06/2023 01:23:00 PM
- DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer • Business Wire • 09/12/2023 12:13:00 PM
- DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference • Business Wire • 09/06/2023 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2023 08:15:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:29:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:25:12 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results • Business Wire • 08/14/2023 08:13:00 PM
- DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 • Business Wire • 08/08/2023 12:32:00 PM
- DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference • Business Wire • 07/18/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM